AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05388162 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Mobile colposcope
Description: It is a comparison trial - Comparing a standard colposcpoe with a smart-phone based colpsocpe.
Study NCT03785886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking group
Description: Subjects in this group perform exercise consisting of walking for 30 - 60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months . Each training includes 5 min warm-up and 5 min cool-down, and the exercise should start after meals for 1 hour . Heart rate is monitored by sports bracelet . Subjects using β-blockers will not use heart rate to monitor exercise intensity , but RPE scores . And RPE( Borg scale) scores are ranged from 11-13.
Study NCT03785886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chinese square dancing group
Description: Chinese square dances have been selected from 24 sets of square dances jointly launched in 2015 and 2017. According to the age and physical health status of the subjects, six dance pieces of are selected as the repertoires of the intervention in this study.~Subjects in this group perform exercise consisting of Chinese square dances for 30-60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months. Each training includes 5 min warm-up and 5 min cool-down , and the exercise should start after meals for 1 hour. Make the subjects step for 30 s to 1 min between each track to adjust the heart rate. Heart rate is monitored by sports bracelet. Subjects using β-blockers will not use heart rate to monitor exercise intensity, but RPE scores. And RPE( Borg scale) scores are ranged from 11-13.
Study NCT03785886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group
Description: Walking group , Chinese square dancing group and control group are given the same health education brochures or health education lectures once a month . Specific contents of the brochure or lecture include : type 2 diabetes , hypertension related medical knowledge and the significance of intervention treatment ; prevention of type 2 diabetes , hypertension nutrition and exercise recommendations ; basic knowledge of scientific exercise and its matters needing attention .
Study NCT00645424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Atorvastatin calcium tablets 10 mg orally once daily in the evening for 12 weeks
Study NCT00645424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Atorvastatin calcium tablets 20 mg orally once daily in the evening for 12 weeks
Study NCT00645424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Atorvastatin calcium tablets 40 mg orally once daily in the evening for 12 weeks
Study NCT02450877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Study NCT02450877 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Arm
Study NCT04999410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: Interventions will contrast alternative training protocols
Study NCT04999410 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Interval Training
Description: Interventions will contrast alternative training protocols
Study NCT02346669 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastroscopy
Description: as detailed in arm description
Study NCT02346669 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: gastroscopy
Description: as detailed in arm description
Study NCT02346669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation
Description: as detailed in arm description
Study NCT03279718 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal Treatment
Description: Scaling and root planing
Study NCT01194154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol-epoetin beta
Description: Methoxy polyethylene glycol-epoetin beta 30 microgram (mcg) subcutaneous injection once monthly up to 24 months with sequential dose adjustments to 50 mcg or 75 mcg depending on change of hemoglobin values of more than 1.0 gram (g)/ deciliter (dL).
Study NCT01194154 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to Methoxy polyethylene glycol-epoetin beta subcutaneous injection once monthly up to 24 months.
Study NCT03219645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo Diterpene Lactone Meglumine Injection
Description: The injection must be added slowly into 0.9% sodium chloride injection and diluted to 250 ml , intravenous drip for about 2 hours.
Study NCT03219645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
Study NCT03219645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetylsalicylic acid
Description: Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
Study NCT04617353 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NO-based treatment of sterno-mediastinitis
Description: Preparation of a postoperative wound in case of infectious complications. A mandatory sampling material for culture and antibiotic sensitivity is collected before and after the air plasma flow treatment.~Direct effect of the air-plasma flow on the entire wound surface in sterilization mode with an exposure of 2-3 minutes for each surgical wound, until the level of bacterial contamination decreases to 10-5 and below.~The technique of using air-plasma flow when closing a wound after preventing infectious complications in it.~In the postoperative period, daily air-plasma flow treatment in sterilization mode along the suture line for 3 minutes. Penetrating drainage NO supply in the biological stimulation mode daily for 10 days, with an exposure of 1-2 minutes up to 10 days, with a volume of up to 2 liters per minute.~Collecting wound culture from the drainage containers on 1-3-7-12 days to detect pathogens and the bacterial number.
Study NCT04617353 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Treatment of sterno-mediastinitis
Description: patients who were treated for sterno-mediastinitis according to clinical guidelines, the main method of which is a permanent irrigation and aspiration flow drainage method, as well as a Vacuum Assisted Closure (VAC) system of dressings for vacuum drainage
Study NCT04267744 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Myia Health® remote patient monitoring unblinded treatment arm
Description: After consenting to the study, the Myia in-home suite of devices will be provided to all recruited patients. The data flowing from the Myia platform will be available to clinicians and patients for the duration of the pilot and utilized to complete study activities.~Device: Myia Health platform and in-home suite of devices®:~Emfit Ballistocardiograph® Withings Connected Scale® VitalScout (VivaLink) ECG Accelerometer® Omron Blood Pressure Monitor® (Sphygmomanometer) Cradlepoint - Hotspot / Adaptor® (LTE Connection) Samsung Galaxy Tab A 8.0® (User Interface)
Study NCT02004587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemigliptin
Description: Gemigliptin is administered to each hepatic impairment subject for single oral dose. Also it is administered to healthy volunteer for single and multiple doses.
Study NCT02004587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin
Description: Gemigliptin is administered to each hepatic impairment subject for single oral dose. Also it is administered to healthy volunteer for single and multiple doses.
Study NCT02975440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: 11 single oral doses of 600 mg Rifampicin resulting in a total dose of 6600 mg Rifampicin.
Study NCT02975440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 2 single oral doses of 1 mg Midazolam resulting in a total dose of 2 mg Midazolam
Study NCT02975440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1002670_Vilaprisan
Description: 2 single oral doses of 4 mg Vilaprisan resulting in a total dose of 8 mg Vilaprisan
Study NCT00724724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butylphthalide Soft Capsules
Description: Butylphthalide Soft Capsules: 2 tablets Bid for 1 year Aspirin: 100mg for 1 year
Study NCT00724724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100mg Qd for 1 year
Study NCT03397927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: orthosis
Study NCT02792010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hip cartilage MRI
Description: Hip cartilage MRI
Study NCT04486963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sanhuangjingshimingwan
Description: Sanhuangjingshimingwan,12g,Bid,6 months.Anti VEGF injection will be injected monthly if needed.
Study NCT04486963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sanhuangjingshimingwan Placebo
Description: Sanhuangjingshimingwan Placebo,12g,Bid,6 months.Anti VEGF injection will be injected monthly if needed.
Study NCT00625521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASF 1096 0.5 % cream applied twice daily
Study NCT00625521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cream vehicle for ASF 1096 cream applied twice daily
Study NCT01928121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care provided by AF expert program
Study NCT00929734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 10mg tablets, once daily in three months
Study NCT00929734 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet, once daily in three months
Study NCT01157182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/Norethindrone acetate
Description: 1/0.5 mg Tablets
Study NCT04141852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of VasQ device
Description: The VasQ external support device (Laminate Medical Technologies, Israel) is a novel Nitinol implant, externally surrounding and supporting the vein and hugging the artery near the junction site, without being in contact with the blood flow.
Study NCT04538092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery Protocol
Description: The investigators have developed an Enhanced Recovery After Surgery protocol for complex spine surgery at UNC. This study will help elucidate the effects of multiple interventions tailored to help patients recover from complex surgery.
Study NCT01157182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Activella®
Description: 1/0.5 mg Tablets
Study NCT03768843 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Harms technique
Description: Atlantoaxial fusion
Study NCT02669862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-101 Solution 40
Study NCT02669862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-101 Solution 45
Study NCT02669862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Solution
Study NCT05164406 — intervention group
Intervention type: PROCEDURE
Intervention: Blood salvage therapy
Description: In the blood salvage group, blood is systematically given back when the minimal amount of blood loss required for reprocessing is met
Study NCT00444509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X
Description: GW685698X will available with a unit dose strength of 400 mcg that will be inhaled via DISKUS
Study NCT00444509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X containing magnesium stearate
Description: GW685698X containing magnesium stearate will available with a unit dose strength of 400 mcg that will be inhaled via DISKUS
Study NCT01124201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stabilization , strengthening and stretching
Description: Interventions were conducted over 6 weeks, twice per week, lasting 30 minutes each. Sessions were supervised by the investigator, and participants were instructed to report any adverse event. Groups were instructed not to participate in any other physical program during the study. Forty-five patients were randomized into three groups namely: Segmental stabilization group (ES)(transversus abdominis and lumbar multifidus), superficial strengthening group (FS)(rectus abdominis, oblique abdominal muscles and erector spinae muscles) and stretching group (AL) (erector spinae, posterior connective tissues and ischiotibials muscles). Patients were evaluated for pain , functional disability,and ability to contract the TrA before and after the treatment.
Study NCT03534063 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: CYP2D6-guided opioid therapy
Description: Using a standardized consult note, recommendations were made to avoid tramadol, hydrocodone, codeine, and oxycodone in PMs, IMs, and UMs and to use an alternative opioid (e.g. morphine, hydromorphone) or non-opioid (e.g. NSAID). Consideration of tramadol as the first-line opioid will be recommended for NMs.
Study NCT01483898 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixmyelocel-T
Description: On Day 14, 20 intramuscular injections of ixmyelocel-T on pre-identified index leg.
Study NCT01483898 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: On Day 14, 20 intramuscular injections of vehicle control on pre-identified index leg.
Study NCT00492856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given orally
Study NCT00492856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given orally
Study NCT04516564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK119
Description: Single dose of AK119 is administered via intravenous infusion to healthy subjects
Study NCT04516564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo is administered via intravenous infusion to healthy subjects
Study NCT03326648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Heavy load strength training performed twice a week for 10 weeks.
Study NCT03326648 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Description: Dietary protein supplement (protein-enriched milk with 0,2 % fat). 0,33 l each day for 10 weeks.
Study NCT02346669 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Fecal Microbiota Transplantation
Description: as detailed in arm description
Study NCT00492856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tretinoin
Description: Given orally
Study NCT03766724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin→Evogliptin+Empagliflozin→Empagliflozin
Description: Evogliptin : Evogliptin 5mg QD, Evogliptin+Empagliflozin : Evogliptin 5mg QD + Empagliflozin 25mg QD, Empagliflozin : Empagliflozin 25mg QD
Study NCT02211014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib
Study NCT04158817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-Labeled PSMA
Description: All participants in the study will be injected with 68Ga-THP-PSMA at a dose of 2.11 MBq/kg in a single dose injection.
Study NCT04158817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-labeled PSMA
Description: Patient will be injected with microdose (\<100 ug) of THP-PSMA
Study NCT01905059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: monoPI - boosted lopinavir or boosted darunavir
Description: boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD) This arm was stopped by the Scientific Committee on advise of the DSMB after interim analysis showing increased risk of failure for these participants. Participants are switched to standard second line triple therapy and will be followed until the last visit at week 96.
Study NCT01905059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bi therapy - (boosted lopinavir or boosted darunavir) + lamivudine
Description: boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) with lamivudine 300 mg QD or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)with lamivudine 300 mg QD. This arm is going on, patients will be followed on this intervention until the end of the study at week 96
Study NCT00922259 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A H7N7 vaccine
Description: Participants will be administered two doses of the candidate vaccine at a dosage of approximately 10\^7.5 50% tissue culture infectious dose (TCID50), in the form of nasal spray. The doses will be administered 28-62 days apart.
Study NCT03766724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin→Evogliptin→Evogliptin+Empagliflozin
Description: Empagliflozin : Empagliflozin 25mg QD, Evogliptin : Evogliptin 5mg QD, Evogliptin+Empagliflozin : Evogliptin 5mg QD + Empagliflozin 25mg QD
Study NCT03766724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin→Evogliptin+Dapagliflozin→Dapagliflozin
Description: Evogliptin : Evogliptin 5mg QD, Evogliptin+Dapagliflozin : Evogliptin 5mg QD + Dapagliflozin 10mg QD, Dapagliflozin : Dapagliflozin 10mg QD
Study NCT01304381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated care
Description: Intervention Multidisciplinary approach and collaboration between specialist palliative and heart failure caregivers, in a shared structured person-centred and identity-promoting care during 6 months
Study NCT03766724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin→Evogliptin→Evogliptin+Dapagliflozin
Description: Dapagliflozin : Dapagliflozin 10mg QD, Evogliptin : Evogliptin 5mg QD, Evogliptin+Dapagliflozin : Evogliptin 5mg QD + Dapagliflozin 10mg QD
Study NCT01304381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated care
Description: One group with 31 participants is offered a multidisciplinary approach and collaboration between specialist palliative and heart failure caregivers in a shared structured person-centred care at home. Assessment of need, length of visits and phone calls are planned to be adapted for each patient. After 6 months (+ - two weeks) the patients will be transferred to usual care provider following an established individual care plan.
Study NCT02513368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: augmentation procedure with Bio-Oss® and Bio-Gide®
Description: soft tissue management using GBR procedure
Study NCT02513368 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: augmentation procedure with connective tissue graft
Description: soft tissue management using the bilaminar technique
Study NCT02397993 — intervention group
Intervention type: PROCEDURE
Intervention: blood collection
Description: blood will be taken for assessment of serum lipase, serum amylase and CA 19-9 prior to EUS-FNA
Study NCT02397993 — intervention group
Intervention type: PROCEDURE
Intervention: fine needle aspiration
Description: During endoscopic ultrasonography, fine needle aspiration will be performed for cytological analysis of the pancreas
Study NCT02397993 — intervention group
Intervention type: PROCEDURE
Intervention: blood collection
Description: blood will be taken 4h after EUS-FNA for assessment of serum lipase, serum amylase and CA 19-9
Study NCT02635737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sentimark
Description: Placement of a metallic clip with paramagnetic properties for tumour localisation
Study NCT00878462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine WHITE raspberry flavor (Treatment A)
Description: Asenapine (Org 5222), 5 mg white raspberry flavored as fast dissolving tablets
Study NCT05727449 — intervention group
Intervention type: PROCEDURE
Intervention: General Anesthesia
Description: General Anesthesia was intruduced for Cesarean Delivery
Study NCT05727449 — intervention group
Intervention type: PROCEDURE
Intervention: Spinal Anesthesia
Description: Spinal Anesthesia was intraduced for Cesarean Delivery
Study NCT04449536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Administration of a single oral dose, using film-coated tablets of either 400 mg or 600 mg or a combination of maximum 3 tablets up to a maximum of 1600 mg
Study NCT01465282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT327 0.05%
Description: 0.05% CT327 (w/w) ointment
Study NCT01465282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT327 0.1%
Description: 0.1% CT327 (w/w) ointment
Study NCT01465282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT327 0.5%
Description: 0.5% CT327 (w/w) ointment
Study NCT01465282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02262195 — intervention group
Intervention type: OTHER
Intervention: Elevated levels of carboxyhemoglobin
Description: Comparison of pulse co-oximeters
Study NCT00485030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cypher
Description: sirolimus-eluting stent
Study NCT00485030 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cypher
Description: sirolimus-eluting stent
Study NCT00485030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xience-V
Description: everolimus-eluting stent